tbuckley/cabot-search huggingface dataset:
PROCUREMENT AND ASSIGNMENT SERVICE MAKES RECOMMENDATIONS TO ALL PHYSICIANS
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
Authors: J. M. Gurney, M. T. Hueman, M. M. Woll, G. B. Ryan, C. E. Storrer, C. Fisher, C. D. Shriver, C. G. Ioannides, S. Ponniah, G. E. Peoples
Journal: Journal of Clinical Oncology (2005)

2575 Background: E75 is an immunogenic peptide from the HER2/neu protein that is highly expressed in breast cancer. We are conducting a clinical trial of an E75 (+GM-CSF) vaccine to assess for safety, immunologic response, and the prevention of clinical recurrences in node-positive breast cancer (NPBC) patients without evidence of disease. Methods: Fifty-three NPBC patients have been enrolled thus far and HLA typed. HLA-A2+ patients (n=24) have been vaccinated while HLA-A2- patients (n=29) are being followed prospectively as clinical controls. Local/systemic toxicities, immunologic responses, and time to recurrence are being measured. Results: Only minor toxicities have occurred (one grade 3 (4%)). All patients have demonstrated clonal expansion of E75-specific CD8+ T cells that lysed HER2/neu-expressing tumor cells. An optimal dosage and schedule have been established. Patients have developed delayed-type hypersensitivity (DTH) reactions to E75 post-vaccination compared to control (33 vs 7 mm, p<0.01). HLA-A2+ patients have been found to have larger, more poorly differentiated, and more hormonally-insensitive tumors compared to the HLA-A2- patients. Despite this, the only two deaths have occurred in the control group. The disease-free survival in the vaccinated group is 85.7% compared to 59.8% in the controls at 22 months median follow-up with a recurrence rate of 8% compared to 21%, respectively (p<0.19). Median time to recurrence in the vaccinated patients was prolonged (11 vs 8 months), and recurrence correlated with a weak DTH response. Conclusions: This HER2/neu (E75) vaccine is safe and effective in eliciting a peptide-specific immune response in vivo. Induced HER2/neu immunity appears to reduce the recurrence rate in high-risk NPBC patients. No significant financial relationships to disclose.
Mearl F. Stanton, M.D.—A Memorial
Journal: JNCI Journal of the National Cancer Institute (1981)

Journal Article Mearl F. Stanton, M.D.—A Memorial Get access JNCI: Journal of the National Cancer Institute, Volume 67, Issue 5, November 1981, Page 959, https://doi.org/10.1093/jnci/67.5.959 Published: 01 November 1981
Emotional Disorders May Become Responsibility of More Physicians
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dance Lesson
Authors: H. S. Meyer
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors.
Authors: Amishi Shah, Shweta Motiwala, Peter J. O'Dwyer, Keith T. Flaherty, Stephen Michael Keefe
Journal: Journal of Clinical Oncology (2013)

384 Background: Tyrosine kinase inhibitors (TKIs) such as sorafenib are widely used in the treatment of solid tumor malignancies. Incident hypertension with angiogenesis inhibitors has been well-documented in the population of patients with renal cell carcinoma (RCC) where incident hypertension on treatment is associated with improved clinical outcome. Little has been reported about increases in blood pressure with TKIs in other solid tumor malignancies. Methods: We performed a retrospective cohort study examining changes in blood pressure with sorafenib among the 101 patients treated at the University of Pennsylvania on a randomized discontinuation trial examining sorafenib in patients with advanced solid tumor malignancies. Solid tumor diagnoses were established on the basis of tumor histology. Treatment of patients on study with sorafenib was initiated at 400 mg BID. Patients were treated for at least 12 weeks and were evaluated at least every three weeks in the clinic. Blood pressure was recorded at each visit. Sorafenib exposure was recorded by patients in a pill diary. The primary endpoint for this study was a maximal change in blood pressure defined as the difference between baseline blood pressure and highest subsequent recorded systolic and diastolic blood pressures on treatment. Results: 72% of RCC patients developed an increase in systolic blood pressure (SBP) of at least 20 mmHg as compared to 32% of non-RCC patients. The mean increase in SBP on study for RCC patients was 30 mmHg versus 19 mmHg in non-mRCC patients. RCC patients in the top quartile of increased SBP showed a mean increase of 54 mmHg as compared to 35 mmHg for non-mRCC patients. A chi-squared test of proportions and t-tests were used to compare rates and means, respectively. Each of the aforementioned differences were found to be statistically significant with p-values &lt;0.003. These relationships also held true for diastolic blood pressure. There was no difference in SBP between groups in terms of age or sorafenib exposure. Conclusions: In these patients treated with sorafenib the proportion of patients with increased blood pressure and the mean amplitude of change in blood pressure both were significantly greater in the RCC population than in the non-RCC group.
Hospital leaders' opinions of the HCFA mortality data
Authors: D. M. Berwick
Journal: JAMA (1990)

The release of hospital-specific mortality data by the Health Care Financing Administration has stirred controversy about the adequacy of current case-mix adjustment models and about the wisdom in general of public release of outcome data. We surveyed a national sample of hospitals, stratified by measured mortality rate, in the 1987 Health Care Financing Administration data release to determine the reactions of hospital leaders to the data and to learn if hospitals with high mortality had different attitudes from those of hospitals with average or low mortality as measured by the Health Care Financing Administration. Seventy-eight percent (N = 195) responded. All hospitals, regardless of mortality rate, shared an extremely negative view of the accuracy, usefulness, and interpretability of the Health Care Financing Administration's mortality data. The lowest possible rating (poor) was given by 70% of the respondents on the question of usefulness of the data to the hospital, by 54% on accuracy of the data, and by 85% on usefulness of the data to consumers. Only 31% of the respondents said that they had used the data at all for internal purposes and 20% reported that the data release had caused problems for the hospital. Hospitals in the high-mortality group were more likely than others to report both use of the data and problems from its release. Publication of outcome data to encourage quality improvement may face severe and pervasive barriers in the attitudes and reactions of hospital leaders who are potential clients for such data. (<i>JAMA</i>. 1990;263:247-249)
Abstract 1738: The I( <i>f</i> )-inhibitor Ivabradine Exerts Vascular Anti-oxidative And Anti-inflammatory Effects Selectively Mediated By Reduction Of Heart Rate
Authors: Florian Custodis, Magnus Baumhaekel, Nils Schlimmer, Franka List, Christoph Gensch, Michael Böhm, Ulrich Laufs
Journal: Circulation (2008)

Objective: In epidemiological studies, elevated resting heart rate (HR) is associated with increased cardiovascular morbidity. We therefore characterized the effects of selective heart rate reduction by inhibition of the I (f) -current by ivabradine (IVA) in mice. Methods and Results: Male ApoE −/− mice fed a high-cholesterol diet were treated with IVA (10 mg/kg/d) or vehicle for 6 weeks (n = 10 per group). IVA reduced HR by 13.4% (472 ± 9 vs 545 ± 11 bpm, p &lt; 0.01) but did not alter blood pressure or lipid levels. Endothelium dependent relaxation of aortic rings was significantly improved in IVA fed animals ( p &lt; 0.01). IVA decreased atherosclerotic plaque size in the aortic root by &gt; 40% and in the ascending aorta by &gt; 70%, p &lt; 0.05. HR reduction had no effect on the number of endothelial progenitor cells in the blood and the bone marrow and did not alter aortic eNOS, p-Akt, VCAM-1 or ICAM-1 expression, but decreased MCP-1 mRNA to 26 ± 7% (p &lt; 0.05). IVA reduced vascular NADPH oxidase activity to 48 ± 6% and decreased L-012 chemiluminescence to 24 ± 9% (both p &lt; 0.05). Lipidperoxidation was reduced to 65 ± 8% in the vasculature of the IVA group compared to vehicle treatment (p &lt; 0.05). DHE fluorescence microscopy in aortic sections detected reduction of ROS release to 62 ± 4% in IVA treated mice (p &lt; 0.01). The in vivo effects of IVA were absent at a dose that did not lower HR and were absent in aortic rings treated ex vivo . Protein expression of p-Akt, eNOS and p-eNOS was not altered in cultured endothelial cells (EC) by increasing doses of Iva. Similarly, NADPH oxidase activity in EC was not changed as well as the Ang II induced free radical release in vascular smooth muscle cells (DCF-fluorescence). Conclusions: Selective HR reduction improves endothelial function and reduces atherosclerotic plaque formation in ApoE −/− mice. Those effects are in part mediated by decreased markers of oxidative stress and downregulation of MCP-1. The control experiments show that a direct effect of IVA on vascular cells is unlikely and support the reduction of heart rate as the primary mechanism of action.
Regional Hospital Staffing
Authors: F. J. Bramble
Journal: BMJ (1972)

<b>Introduction:</b> A dysregulation between pro-inflammatory and pro-resolution mediators has been proposed as a potential contributor to chronic persistent inflammation in bronchiectasis. <b>Aim:</b> The aim of this study was to characterise lipids in the blood and airways in clinically stable bronchiectasis patients. <b>Methods:</b> 6 healthy volunteers, 10 mild, 15 moderate and 9 with severe bronchiectasis were recruited whilst clinically stable. All participants had blood taken and underwent bronchoscopy [bronchoalveolar lavage (BAL) and brushings obtained]. Lipids were measured by liquid chromatography and mass spectrometry and transcription of lipoxin A4 biosynthetic enzymes [5 Lipoxygenase(LOX), LTA4 hydrolase, 15LOX-A and 15LOX-B] was assessed by qRT-PCR. The AA metabolite lipids assessed were: anti-inflammmatory and pro-resolution Lipoxin A4, and the generally classified pro-inflammatory mediators Prostaglandin (PG)E2, 5 hydroxyeicosatetraenoic acid (5-HETE), 15 hydroxyeicosatetraenoic acid (15-HETE), Leukotriene (LT)B4 and 9-hydroxyoctadecadienoic acid (9-HODE). <b>Results:</b> In serum, there were significantly lower levels of Lipoxin A4 and higher levels of PGE2, 15HETE and LTB4 in moderate/severe disease compared to healthy controls, p=0.04, p=0.03, p=0.03 and p=0.02 respectively. In BAL, significantly higher levels of PGE2, 5-HETE, 15-HETE, 9 HODE and LTB4 in moderate/severe disease compared to healthy donors, p&lt;0.0001, p=0.004, p=0.005, p=0.04 and p&lt;0.0001 respectively. LTA4 hydrolase was the most abundantly expressed RNA in bronchial brushings, and 15LOX-B the least abundant gene. <b>Conclusion:</b> Dysregulation of LXA4 biosynthetic genes shift the balance to a pro-inflammatory mediator profile contributing towards persistent inflammation.
Respiratory Effects in Toluene Diisocyanate Manufacture: A Multidisciplinary Approach
Authors: Hans Weill, John Salvaggio, Arthur Neilson, Brian Butcher, Morton Ziskind
Journal: Environmental Health Perspectives (1975)

A new plant manufacturing toluene diisocyanate (TDI) has provided a unique opportunity to investigate the effects of TDI vapor inhalation on respiratory health in a group of exposed workers who have been studied prior to the start of plant operation. In order to establish dose-response relationships and determine host factors, complete biologic monitoring, including pulmonary function and immunologic studies, has been performed concurrently with a comprehensive environmental monitoring program including continuous sampling for atmospheric concentrations of TDI. Study groups include workers with regular exposure to TDI in production jobs (83), workers with intermittent contact with this vapor, usually in maintenance (28), and a control group of workers employed outside the TDI area (55). This population is being followed for a period of 5 yr. The plant began operations in August 1973 with start-up procedures completed by the end of October. TDI spills occurred for numerous reasons, usually attributed to pump failure and resultant line blockage. Significant exposures also occurred in the drumming operation. The influence of these malfunctions is noted in the continuous monitoring data on atmospheric TDI concentrations which continue to reveal frequent excursions above the threshold limit value (TLV) of 0.02 ppm ceiling. These data are presented in relation to time and plant location. Although the first full year follow-up following initial exposure was not complete, certain preliminary clinical observations were made. A number of workers had episodes of acute respiratory symptoms related to single exposure to an irritant gas at work, usually either TDI or phosgene. It appears that two or three workers in the study population have become "clinically sensitized" to TDI and have been removed from regular TDI exposure. To date, the total number of workers who report the presence of recurring respiratory symptoms has not increased in comparison with the pre-exposure survey. Pulmonary function data after one full year of TDI exposure are not yet available. Pre- and post-shift ventilatory function studies do not indicate significant differences between the exposed and control groups. Selected individuals had carefully controlled inhalation challenge tests to monitored concentrations of TDI vapor under laboratory conditions. In workers suspected of having become "sensitized", immediate and/or late air flow obstruction was demonstrated and could be related to dose of inhaled TDI.
Extracellular DNA Traps Are Associated with Pathogenesis of TRALI in Humans and Mice
Authors: Grace M. Thomas, Carla Carbo, Brian Curtis, Kimberly Martinod, Irina B. Mazo, Daphne Schatzberg, Stephen M. Cifuni, Tobias A. Fuchs, Ulrich H. von Andrian, John H. Hartwig, Richard H. Aster, Denisa D. Wagner
Journal: Blood (2011)
Primary tuberculous complex of the skin
Authors: C. A. Pereira
Journal: JAMA (1976)

A 7-YEAR-OLD girl who had symptoms of suppurative inguinal lymphadenitis proved to have an unusual type of skin tuberculosis: a primary complex involving the skin of the foot and the draining inguinal lymph nodes. This case is being reported because of the rarity of this lesion and the consequences of an incorrect diagnosis. A primary (Ghon) complex involving skin and inguinal lymph nodes is encountered infrequently.<sup>1</sup>The skin lesion may be insignificant and easily overlooked; the associated lymphadenopathy is difficult to differentiate from that produced by other diseases. Children are most often affected.<sup>2</sup>Incorrect diagnosis may lead to chronicity of symptoms, inappropriate surgical procedures, and dissemination of the disease. The identification of tuberculous contacts is important for the detection of tuberculosis. <h3>Report of a Case</h3> A 7-year-old girl was admitted to the Miriam Hospital with a painful lump in the right groin, which had been present for four
Intermediate-range sweat chloride concentration and Pseudomonas bronchitis. A cystic fibrosis variant with preservation of exocrine pancreatic function
Authors: R. C. Stern
Journal: JAMA (1978)

We studied the clinical and laboratory characteristics of seven patients with sweat chloride concentrations consistently between 40 and 60 mEq/liter. Each has chronic<i>Pseudomonas</i>bronchitis, and all lack digestive symptoms. Laboratory findings indicate the preservation of exocrine pancreatic function. The patients include two of five children in one family and two of four in another. In a third family, one of five siblings has an intermediate sweat chloride concentration, but another has a typical fibrosis value (105 mEq/liter). One patient died of respiratory failure; results of an autopsy showed bronchiolectasis typical of cystic fibrosis, but minimal pancreatic changes. The data suggest a genetic basis for this variant of cystic fibrosis. These patients may be homozygous for a portion of a closely linked multigene cystic fibrosis locus or may have modifier genes that ameliorate the pancreatic and sweat lesions. (<i>JAMA</i>239:2676-2680, 1978)
Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma.
Authors: Matheus Bongers Alessandretti, Raphael Brandao Moreira, Erika Pereira Brandao, Jessica Ribeiro Gomes, Marcus Paulo Fernandes Amarante, Aline Da Rocha Lino, Rodnei Merlrina Martins Junior, Carina Mina Abrahao, Tarcia Tarciane Soares de Sousa, Renata D'Alpino Peixoto, Marcelo Rocha Cruz, Fernando C. Maluf, Antonio C. Buzaid
Journal: Journal of Clinical Oncology (2015)

468 Background: There is only limited data regarding efficacy and safety of FOLFIRINOX in elderly patients with advanced pancreatic adenocarcinoma. We aim to evaluate our experience with dose-reduced FOLFIRINOX in patients &gt; 65 years-old. Methods: All patients &gt; 65 years-old with biopsy-proven advanced pancreatic adenocarcinoma who received at least one cycle of modified dose-attenuatedFOLFIRINOX (no bolus FU and reduced dose of oxaliplatin and/or irinotecan) at our institution were identified. Results: Twenty-one consecutive patients (62% males) were reviewed. Median age was 67 (range 65-79). Grade 3/4 toxicities were reported in 7 (33%) patients ; the most common toxicities were anemia (62%), and nausea/vomiting (45%). Elevations in AST and/or ALT above the upper limit of normality were identified in 38%. No deaths due to toxicities were reported. Prophylactic granulocyte colony stimulator factor (G-CSF) was given in 16 (70 %) patients. Dose reductions were substantial with median reductions of 27,8 % (range 15 - 50%) for 5-FU, 27,1% (range 6-50%) for oxaliplatin and 25% (range 12-75%) for irinotecan. Median overall survival (OS) was 11,8 months (95% CI 10,2 - 13,3). Median progression free survival (PFS) was 6,9 months (95% CI 5,3 - 8,5). Conclusions: Modified dose-attenuated FOLFIRINOX is a reasonable option for elderly patients with advanced pancreatic adenocarcinoma. Adverse events were manageable and no deaths due to toxicity were reported. Median OS and PFS were similar to the pivotal phase III trial, demonstrating that dose-attenuated FOLFIRINOX may be beneficial to elderly patients.
Ocular Trauma
Authors: Peter H. Morse
Journal: JAMA (1980)

The stated objective of this book is to provide a practical, referenced text on the management of ocular trauma. The scope of the book is broad, including an initial discussion of history taking, examination, roentgenographic evaluation, ultrasound, electroretinography, and visual-evoked response. Subsequent chapters deal with diagnosis and treatment of trauma through the eyelids and orbit, anterior segment trauma, intraocular foreign bodies, and trauma involving the vitreous, choroid, retina, extraocular muscles, and optic pathways. Other sections deal with social and legal implications of the treatment of trauma in sports, injury prevention, enucleation, evisceration, extrusion of implants, reconstruction of ocular sockets, sympathetic ophthalmitis, and even articles on research directions in ocular trauma. This work evolved from articles presented at the Congress on Ocular Trauma, and, in compiling the work and viewpoints of so many different authors, is a notable achievement. As with any such work, however, it does suffer from a certain